Becker's Healthcare November 17, 2022
Paige Twenter

As the team of 33 at Mark Cuban Cost Plus Drug Co. works to serve its 1.3 million customers, Mr. Cuban told Time his planned next steps for the company that looks to disrupt the $1.4 trillion pharmaceutical industry. 

Since its launch in January, Cost Plus Drug Co. has gone from selling 100 drugs to about 1,000 — some of which cost more than 90 percent less than the market price — but it has yet to break into larger pieces of the market, such as brand-name drugs. In October, the company partnered with its first payer, Capital Blue Cross, and Mr. Cuban said he expects to take more insurance plans in 2023. 


Today's Sponsors


Today's Sponsor

Health Edge

Topics: Pharma, Pharma / Biotech
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Amazon’s RxPass Doesn’t Yet Really Compete With Mark Cuban’s Cost Plus Drug Company
2023’s Biggest Pharma Cybersecurity Threats to Watch
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article